GlassScriptPhysician profile
Rachel V Kramer
NPI 1932108875
$16,288.97
in general payments reported to CMS, 2019-2025
82 companies · $2,561 in 2025
The $2,561 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,170 · 2020: $1,774 · 2021: $2,428 · 2022: $1,896 · 2023: $2,192 · 2024: $2,268 · 2025: $2,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,790 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,789.68 |
| Education | $231.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,226.89 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $1,069.33 | 2019-2025 | Saphnelo, Enhertu |
| Janssen Biotech, INC. | $949.52 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| Seagen INC. | $781.71 | 2020-2023 | Tukysa, Adcetris |
| Pfizer INC. | $734.85 | 2019-2025 | |
| Genzyme Corporation | $696.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $695.31 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $624.76 | 2019-2024 | Enhertu, Injectafer |
| Lilly USA, LLC | $569.82 | 2019-2025 | Verzenio, Jaypirca, Omvoh |
| Glaxosmithkline, LLC. | $562.97 | 2019-2025 | Ojjaara, Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $479.60 | 2019-2025 | |
| Incyte Corporation | $451.67 | 2019-2025 | Jakafi |
| Celgene Corporation | $416.83 | 2019-2025 | Reblozyl, Pomalyst |
| Sobi, INC | $402.78 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $344.12 | 2019-2025 | Entyvio, Hyqvia |
Show all 82 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.